Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide

Journal of Medical Microbiology

Volumn 57, Issue 9, 2008, Pages 1129-1134

  Gu, Peihua ^a   Constantino, Luis ^b   Zhang, Ying ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

4 DODECYLOXYLBENZOIC ACID; BENZAMIDE DERIVATIVE; BENZOIC ACID ESTER DERIVATIVE; DICYCLOHEXYLCARBODIIMIDE; PROPYLHYDROXYBENZOIC ACID; PYRAZINAMIDE; PYRAZINOIC ACID; SODIUM AZIDE; UNCLASSIFIED DRUG;

ANAEROBIC GROWTH; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM COLONY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENERGY METABOLISM; HELICOBACTER PYLORI; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN TENSION; PRIORITY JOURNAL;

ACIDS; ANAEROBIOSIS; ANTITUBERCULAR AGENTS; ENERGY METABOLISM; MOLECULAR CONFORMATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 51149085652     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.2008/000786-0     Document Type: Article

References (16)

1. Christensen, H., Garton, N. J., Horobin, R. W., Minnikin, D. E. & Barer, M. R. (1999). Lipid domains of mycobacteria studied with fluorescent molecular probes. Mol Microbiol 31, 1561-1572.
2. Constantino, L., Rosa, E. & Iley, J. (1992). The microsomal demethylation of N,N-dimethylbenzamides. Substituent and kinetic deuterium isotope effects. Biochem Pharmacol 44, 651-658.
3. Raviglione, M. C. (2003). The TB epidemic from 1992 to 2002. Tuberculosis (Edinb) 83, 4-14.
4. Robinson, J. R. & Matheson, L. E. (1969). Linear free-energy relationship between alcohol pKa and solvolysis rates of esters where substituent variation is in the alkyl portion of the ester. J Org Chem 34, 3630-3633.
5. Schaller, A., Guo, M., Gisanrin, O. & Zhang, Y. (2002). Escherichia coli genes involved in resistance to pyrazinoic acid, the active component of the tuberculosis drug pyrazinamide. FEMS Microbiol Lett 211, 265-270.
6. Sun, Z. & Zhang, Y. (1999a). Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother 43, 537-542.
7. Sun, Z. & Zhang, Y. (1999b). Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber Lung Dis 79, 319-320.
8. Testa, B. (2004). Prodrug research: futile or fertile? Biochem Pharmacol 68, 2097-2106.
9. Wade, M. M. & Zhang, Y. (2004). Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 53, 769-773.
10. Wade, M. M. & Zhang, Y. (2006). Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 58, 936-941.
11. Wade, M. M., Volokhov, D., Peredelchuk, M., Chizhikov, V. & Zhang, Y. (2004). Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis 49, 89-97.
12. Zhang, Y. (2005). The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 45, 529-564.
13. Zhang, Y. & Mitchison, D. (2003). The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7, 6-21.
14. Zhang, Y., Scorpio, A., Nikaido, H. & Sun, Z. (1999). Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181, 2044-2049.
15. Zhang, Y., Wade, M. M., Scorpio, A., Zhang, H. & Sun, Z. (2003a). Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52, 790-795.
16. Zhang, Y., Zhang, H. & Sun, Z. (2003b). Susceptibility of Mycobacterium tuberculosis to weak acids. J Antimicrob Chemother 52, 56-60.